L01DB02 - Daunorubicin |
Propably not porphyrinogenic |
PNP |
Rationale
Substrat of CYP3A4, but no indications of CYP-inducing or inhibiting capacity.
Chemical description
Daunorubicin is an antineoplastic anthracycline antibiotic.
Therapeutic characteristics
Daunorubicin is used in the treatment of acute lymphoblastic and myeloid leucemias, often in combination with other anti-neoplastic drugs. Administered as iterated intravenous infusions. Diarrhoea is a common adverse reaction of daunorubicin that can be confused with symptoms of an acute porphyric attack.
Metabolism and pharmacokinetics
Daunorubicin is rapidly metabolised in the liver by NADPH cytochrome P450 reductase. Baumhakel (2001) found that daunorubisin had only a minor inhibitory effect on human CYP3A4. Substrate of CYP3A4. No interactions described pointing to interference with CYP-metabolism of other drugs. Not listed as CYP 3A4 or 2C9 -inducer or inhibitor by Rendic (2002).
IPNet drug reports
No.
References
- Scientific articles
- Rendic, S. Summery of information on human CYP enzymes: human P450 metabolism. Drug metabolism reviews 2002; 34(1&2), 83-448. #1025
- Baumhäkel M, Kasel D, et al. Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther 2001;39(12):517-28. PMID 11770832. #4579
- Drug reference publications
- McEvoy GK, editor. Daunorubicin. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (04.05.10). #2006
- Sweetman SC, editor. Martindale: The complete drug reference. Daunorubicin. Pharmaceutical Press 2009. #2008
- Summary of Product Characteristics
- Norwegian medicines agency. Summary of Product Characteristics (SPC). Cerubidin. #2007
Similar drugs
© NAPOS 2024